ATP synthase membrane subunit eGenealiases: ATP5I · ATP5K
Q-omics provides the consensus-scored ATP5ME profile across patient tissues and cancer cell-line models. ATP5ME expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP5ME is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ATP5ME protein abundance shows 21,681 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where ATP5ME shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5ME — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5ME survival associations across molecular data types. ATP5ME RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5ME RNA expression–survival associations across cancer types. High ATP5ME expression shows unfavorable associations in UVM, LUAD, HNSC, UCS, KIRC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP5ME RNA expression.
This table summarizes ATP5ME tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATP5ME. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5ME shows lower tumor expression in COAD and HNSC and higher tumor expression in BRCA, LIHC, LUSC and CHOL. The COAD box plot shows higher ATP5ME RNA expression in normal versus tumor tissue (log2 FC = −0.811, t-test p < 0.001).
This table shows molecular features associated with ATP5ME in patient tissues and cancer cell lines. In patient samples, ATP5ME shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5ME RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
